Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. drug application
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Books
Downloads
Videos

Refine by
Date

  • This Year
  • Older

Drug Application Articles & Analysis

161 news found

Proregulations' Comprehensive EU MAA Solutions

Proregulations' Comprehensive EU MAA Solutions

Obtaining the Marketing Authorisation Application (MAA) is a key step in the commercialization of drugs in the EU, and also an important help to promote the global market expansion of pharmaceutical companies. ...

ByProregulations


Proregulations Launches Comprehensive ANDA Services   

Proregulations Launches Comprehensive ANDA Services  

An Abbreviated New Drug Application (ANDA) is an application submitted to the U.S. FDA to demonstrate that a generic drug is equivalent to a previously approved Reference Listed Drug (RLD) in terms of safety, efficacy, and quality. ...

ByProregulations


Biopharma PEG Announces FDA DMF Registration for mPEG-pALD (20K)

Biopharma PEG Announces FDA DMF Registration for mPEG-pALD (20K)

Biopharma PEG, a leading manufacturer of high-quality polyethylene glycol (PEG) derivatives, today announced that its mPEG-pAld (20K) product has successfully achieved DMF (Drug Master File) registration with the U.S. Food and Drug Administration (FDA) under DMF number 040600. ...

ByBiopharma PEG Scientific Inc


Huateng Pharma's mPEG-pALD Receives FDA DMF Filing Approval

Huateng Pharma's mPEG-pALD Receives FDA DMF Filing Approval

(Huateng Pharma), a global leader in the development and production of high-quality PEG derivatives, is pleased to announce that its mPEG-pALD (20K) has successfully completed its Drug Master File (DMF) filing with the U.S. Food and Drug Administration (FDA), under DMF No. 040600. ...

ByHunan Huateng Pharmaceutical Co. Ltd.


Biopharma PEG Offers 30% Thanksgiving Discount on Monodispersed PEGs

Biopharma PEG Offers 30% Thanksgiving Discount on Monodispersed PEGs

This special offer is valid through December 4, 2024, at 23:59 EST.Our monodispersed PEGs are highly versatile and indispensable in various pharmaceutical and biotechnological applications. These precision-engineered compounds are widely used in PEGylation, a process that enhances the pharmacokinetics and stability of therapeutic molecules. They are also critical components in ...

ByBiopharma PEG Scientific Inc


CD Formulation Is A Reliable Provider of Customized Drug Conjugates Services

CD Formulation Is A Reliable Provider of Customized Drug Conjugates Services

In the rapidly evolving landscape of pharmaceutical innovations, CD Formulation emerges as a key player, offering customized drug conjugates services that cater to the rising demands for advanced drug development. ...

ByCD Formulation


Innovations in Medical Devices and Materials Used

Innovations in Medical Devices and Materials Used

Among the various materials used in medical device design, polytetrafluoroethylene (PTFE tubing) has emerged as a standout choice, particularly in applications such as catheters and drug delivery systems. This article explores the role of advanced materials like these in driving innovation in medical devices, focusing on their benefits and implications for the ...

ByFluorostore


CD Bioparticles Introduces New Polyolefin Family Polymers for Drug Delivery Applications

CD Bioparticles Introduces New Polyolefin Family Polymers for Drug Delivery Applications

CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has recently expanded its low PDI polymer portfolio and announces its new offering of Polyolefin Family polymers with a wide range of properties that make them well-suited for a variety of drug delivery applications. ...

ByCD Bioparticles


Microneedle Market Projected to Reach $1.3 Billion by 2028, Reveals Latest BCC Research Study

Microneedle Market Projected to Reach $1.3 Billion by 2028, Reveals Latest BCC Research Study

Boston: Microneedle technology, driven by high demand in dermatologic procedures and its versatile applications in drug delivery, vaccine administration, and disease diagnostics, faces challenges in its complex manufacturing process. ...

ByBCC Research


Creative Enzymes Unveils Advanced Substrate, Inhibitor, and Ligand Screening Services

Creative Enzymes Unveils Advanced Substrate, Inhibitor, and Ligand Screening Services

The screening of substrates, inhibitors, and other ligands is a pivotal facet of enzyme research, enabling scientists to pinpoint compounds best suited for a variety of applications, from drug development to industrial processes. A profound understanding of enzyme-molecule interactions can pave the way for groundbreaking therapies, improved bioprocessing, and the ...

ByCreative Enzymes


Alfa Chemistry: Custom Design Takes Organs-On-Chips to the Next Level

Alfa Chemistry: Custom Design Takes Organs-On-Chips to the Next Level

This cutting-edge technology provides scientists and researchers with an innovative platform to study human organs in a way that was previously impossible, promising to accelerate drug discovery, reduce the need for animal testing and ultimately transform the future of medicine. ...

ByAlfa Chemistry


Ionis Announces Fda Acceptance Of New Drug Application For Eplontersen For The Treatment Of Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (Attrv-Pn)

Ionis Announces Fda Acceptance Of New Drug Application For Eplontersen For The Treatment Of Hereditary Transthyretin-Mediated Amyloid Polyneuropathy (Attrv-Pn)

CARLSBAD, Calif., March 7, 2023 /PRNewswire/ -- Ionis Pharmaceuticals (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for eplontersen, an investigational antisense medicine for the treatment of people living with hereditary transthyretin-mediated amyloid ...

ByHeart Failure Society of America, Inc. (HFSA)


BMG LABTECH and InvivoSciences, Inc. Initiate Market Collaboration To Accelerate Drug Discovery in Engineered 3D Tissues

BMG LABTECH and InvivoSciences, Inc. Initiate Market Collaboration To Accelerate Drug Discovery in Engineered 3D Tissues

The ultra- sensitive plate reader, CLARIOstar®, will analyze rapid beat-to-beat changes (up to 50 Hz) in the fluorescence intensities of dyes that indicate physiological states in engineered 3D heart tissue after drug/compound application. In addition, InvivoSciences, Inc. is sponsoring a workshop during Cell Based Assays Summit in Munich Germany, December ...

ByInvivoSciences, Inc. (IVS)


Bayer progressing well with transformation of pharma business and raises peak sales potential of key growth drivers to over twelve billion euros

Bayer progressing well with transformation of pharma business and raises peak sales potential of key growth drivers to over twelve billion euros

This improved outlook comes amid the company’s potential blockbuster drugs tracking ahead of schedule and targeted investments in Research and Development (R&D) replenishing its pharmaceutical development pipeline. ...

ByBayer AG


Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD

Cingulate Initiates Phase 3 Study of Lead Asset CTx-1301, Designed as a True Entire Active-Day Treatment for ADHD

Food and Drug Administration (FDA) for the treatment of attention deficit/hyperactivity disorder (ADHD). ...

ByCingulate


Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-037 (CD73 Inhibitor) in Combination with KEYTRUDA (pembrolizumab)

Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-037 (CD73 Inhibitor) in Combination with KEYTRUDA (pembrolizumab)

“Antengene believes that cancer treatments involving the rational combination of immuno-oncology drugs and targeted therapies may offer the greatest opportunity for substantial advances in treatment outcomes for patients with cancer,” said Dr. ...

ByAntengene Corporation Limited


Antengene Announces NDA Submission for XPOVIO in Macau,China, Malaysia and Thailand for Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-cell Lymphoma

Antengene Announces NDA Submission for XPOVIO in Macau,China, Malaysia and Thailand for Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-cell Lymphoma

Shanghai and Hong Kong, PRC, December 23, 2022 — Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted New Drug ...

ByAntengene Corporation Limited


Eagle Pharmaceuticals Receives FDA Approval for Additional Indication for PEMFEXY in Combination with Pembrolizumab and Platinum Chemotherapy

Eagle Pharmaceuticals Receives FDA Approval for Additional Indication for PEMFEXY in Combination with Pembrolizumab and Platinum Chemotherapy

(Nasdaq: EGRX) (“Eagle” or the “Company”) announced today that the U.S. Food and Drug Administration (“FDA”) has approved an additional indication for PEMFEXY® (pemetrexed injection) in combination with pembrolizumab and platinum chemotherapy for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer ...

ByEagle Pharmaceuticals, Inc.


Molecular Devices adds proprietary patient-derived organoid technology with acquisition of Cellesce

Molecular Devices adds proprietary patient-derived organoid technology with acquisition of Cellesce

Molecular Devices, LLC., a leading provider of high-performance life science solutions, today announced the acquisition of Cellesce Ltd (“Cellesce”) which specializes in contract development and manufacturing of large scale patient-derived organoids (PDOs) for diverse applications, including drug screening. Drug efficacy and toxicity ...

ByMolecular Devices, LLC.


Terray Therapeutics Strengthens Leadership with Appointment of Bassil Dahiyat, Ph.D., as Board Independent Director

Terray Therapeutics Strengthens Leadership with Appointment of Bassil Dahiyat, Ph.D., as Board Independent Director

Terray Therapeutics, a biotechnology company accelerating drug discovery through the application of computational approaches to precisely generated chemical data at scale, today announced the appointment of Bassil Dahiyat, Ph.D., as an Independent Director. ...

ByTerray Therapeutics, Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT